Dermatomyositis in the Elderly — Presentation, Comorbidities, Investigations, Treatment and Prognosis

Dermatomyositis is an idiopathic inflammatory myopathy combining characteristic cutaneous features with symmetrical proximal muscle weakness.

The mechanism is humoral and complement-mediated: deposition of the C5b-9 membrane attack complex on endomysial capillaries causes capillary dropout and ischaemia of the periphery of the fascicle — hence the pathognomonic perifascicular atrophy on muscle biopsy. This contrasts with polymyositis and inclusion body myositis, which are CD8+ T-cell mediated.

The disease has a bimodal age distribution; the adult peak is in the fifth to sixth decades, and elderly onset carries the highest malignancy risk of any myositis subtype.

Skin changes often precede muscle disease by weeks to months: the heliotrope rash (violaceous periorbital discoloration with oedema) and Gottron’s papules over the MCP, PIP and DIP joints, with Gottron’s sign over elbows and knees.

Photodistributed erythema: the shawl sign (upper back and shoulders), V-sign (anterior chest and neck), holster sign (lateral thighs, notably a non-sun-exposed site), and facial erythema.

Other cutaneous signs: periungual erythema with dilated, tortuous nailfold capillary loops and ragged cuticles, mechanic’s hands (hyperkeratotic fissured lateral fingers, associated with the anti-synthetase syndrome), poikiloderma, calcinosis cutis (less common in adults than in juvenile disease), and intense pruritus — a prominent and frequently overlooked complaint.

Muscle involvement: insidious symmetrical proximal weakness — difficulty rising from a chair or toilet, climbing stairs, combing hair and hanging out clothes. Pain is not prominent, and neck flexor weakness is characteristic.

The critical geriatric pitfall: proximal weakness in an older person is easily misattributed to normal ageing, sarcopenia, deconditioning, polymyalgia rheumatica, statin myopathy, hypothyroid myopathy or steroid myopathy — leading to dangerous delay in diagnosis and malignancy search.

Dysphagia from pharyngeal and upper oesophageal striated muscle involvement occurs in up to a third; it predicts aspiration pneumonia and death, and may be accompanied by dysphonia and nasal regurgitation.

Clinically amyopathic dermatomyositis accounts for about 20% of cases — the classical rash with no clinically evident weakness. It still carries the full risk of malignancy and interstitial lung disease and must be investigated identically.

Malignancy is the dominant geriatric concern. Cancer-associated myositis is defined as a malignancy occurring within 3 years before or after the myositis diagnosis. Some myositis develops as a paraneoplastic syndrome, and treating the tumour often improves the myositis.

Anti-TIF1-γ (anti-p155) is the key marker — present in about 7–15% of dermatomyositis overall but in more than half of cancer-associated myositis; roughly 40% of anti-TIF1-γ-positive patients have a malignancy, with the association strongest in the elderly. Anti-NXP2 is also malignancy-associated and causes calcinosis and dysphagia.

Commonest associated tumours: ovary, lung, breast, stomach, colorectum and pancreas in Western series; nasopharyngeal carcinoma is over-represented in Asian populations — highly relevant in the Indian context.

Interstitial lung disease occurs in 20–40%. Anti-MDA5 predicts rapidly progressive ILD with a characteristic ulcerating cutaneous vasculopathy and palmar papules, and carries the worst prognosis of all subtypes. Anti-synthetase syndrome (anti-Jo-1 and others) = myositis, ILD, arthritis, Raynaud’s, fever and mechanic’s hands.

Cardiac involvement: myocarditis, conduction defects, arrhythmias and heart failure — a leading cause of death; there is also accelerated atherosclerosis.

Other comorbidities: aspiration pneumonia, venous thromboembolism, glucocorticoid-induced osteoporosis and fracture, infection, severe deconditioning and sarcopenia, and overlap syndromes with systemic sclerosis, SLE and Sjögren’s syndrome.

Muscle enzymes: creatine kinase, aldolase, LDH, AST and ALT. Note two traps — CK may be normal in amyopathic disease and is often relatively lower in the elderly because of reduced muscle mass; and the raised transaminases produce a false “hepatitis” pattern that is actually muscle in origin.

Autoantibodies are now central. Check ANA, then an extended myositis panel for myositis-specific antibodies (anti-TIF1-γ, NXP2, MDA5, Mi-2, SAE and the synthetases) and myositis-associated antibodies (PM-Scl, Ro52, U1-RNP). These define phenotype, malignancy risk and prognosis better than any other single test.

Electromyography: a myopathic irritative pattern — short-duration, small-amplitude polyphasic motor unit potentials with fibrillations, positive sharp waves and increased insertional activity.

MRI of the thighs with T2/STIR sequences shows patchy muscle oedema, guides the biopsy site, and distinguishes active inflammation from irreversible fatty replacement — useful in the elderly for deciding whether persistent weakness warrants more immunosuppression.

Muscle biopsy: perifascicular atrophy, perimysial and perivascular infiltrate of CD4+ T cells, B cells and plasmacytoid dendritic cells, capillary dropout with MAC deposition, and MHC class I upregulation. Skin biopsy shows interface dermatitis indistinguishable from lupus.

Malignancy screening is mandatory in every patient over 40. Baseline: full history and examination including breast, pelvic, rectal and lymph node assessment; complete blood count, biochemistry, urinalysis and faecal occult blood; chest radiograph; age- and sex-appropriate screening (mammography, cervical cytology, PSA, colonoscopy); and CA-125 with transvaginal ultrasound in women. High-risk patients need CT of chest, abdomen and pelvis, with FDG-PET/CT considered, repeated annually for 3 years.

Organ-specific baseline work-up: HRCT chest and pulmonary function tests with DLCO for ILD; ECG, troponin and echocardiography for cardiac involvement; and videofluoroscopic swallow assessment if there is any dysphagia.

Prednisolone 0.5–1 mg/kg/day is first-line, tapered over 6–12 months once strength improves. Use IV methylprednisolone pulses for severe disease, dysphagia, cardiac involvement or rapidly progressive ILD.

Start a steroid-sparing agent early in older people to limit steroid toxicity: methotrexate or azathioprine first-line; mycophenolate mofetil, particularly with ILD; calcineurin inhibitors (tacrolimus, ciclosporin) for anti-MDA5 ILD; and cyclophosphamide or rituximab for refractory or severe disease.

Intravenous immunoglobulin 2 g/kg is effective in refractory disease, in dysphagia, and where immunosuppression is hazardous (active infection or malignancy) — but watch for thromboembolism, volume overload and renal impairment in older patients.

Skin disease requires its own plan: rigorous photoprotection, topical corticosteroids and calcineurin inhibitors, hydroxychloroquine, and antipruritics — cutaneous disease often persists after myositis has responded.

Supportive and geriatric care matters as much as immunosuppression: early physiotherapy and graded resistance exercise (no longer contraindicated and now recommended), speech and swallow therapy with texture modification and aspiration precautions, nutritional support, VTE prophylaxis, bone protection with calcium, vitamin D and a bisphosphonate, Pneumocystis prophylaxis, glucose monitoring, vaccination and falls prevention.

Treat any underlying malignancy — the myositis frequently improves with successful tumour therapy, which justifies an aggressive and repeated cancer search.

Poor prognostic factors: older age, malignancy, interstitial lung disease (especially anti-MDA5), dysphagia, cardiac involvement, delayed treatment, and severe weakness at presentation.

Malignancy-associated dermatomyositis has substantially higher mortality; overall survival in elderly-onset disease is markedly worse than in younger patients. The leading causes of death are cancer, aspiration pneumonia, interstitial lung disease, cardiac disease and infection.

Functional recovery is often incomplete — residual weakness, fatigue and deconditioning are common, so rehabilitation goals should be functional and realistic, focused on activities of daily living, transfers and safe swallowing rather than complete normalisation of strength.